Trial Profile
A PHASE 1, DOUBLE-BLIND (3RD PARTY OPEN), RANDOMIZED, PLACEBO-CONTROLLED, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF REPEAT ORAL DOSES OF PF-06372865 IN HEALTHY ADULT SUBJECTS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Darigabat (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 10 Dec 2019 Results assessing safety, tolerability and pharmacokinetics of multiple repeated Doses of the PF-06372865 presented at the 73rd Annual Meeting of the American Epilepsy Society
- 08 Dec 2019 According to a Cerevel Therapeutics media release, the data from this study were presented at the American Epilepsy Society (AES) 2019 Meeting.
- 08 Dec 2019 Results presented in a Cerevel Therapeutics media release.